Publications directory

Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm

The web Directory of Information Materials for People Affected by Cancer is regularly updated and currently has details of over 1,900 booklets, leaflets, books and audiovisual materials for people affected by cancer. Most have been published in the last five years but we have included some older ones that are still useful.

Results: 142

Cover image of 'Rituximab for lymphoma'

Rituximab for lymphoma (February 2020)

Lymphoma Action

This factsheet is about the monoclonal antibody rituximab in the treatment of lymphoma. It tells you how rituximab works, who might be given it and what to expect during treatment. 

Cover image of 'Targeted drugs for lymphoma'

Targeted drugs for lymphoma (January 2020)

Lymphoma Action

This factsheet is about targeted drugs: What are targeted drugs?; Who can have targeted drugs?; What targeted drugs are approved for lymphoma?; Lymphoma research and drugs in development.

Cover image of 'Venetoclax'

Venetoclax (February 2020)

Lymphoma Action

Venetoclax is a targeted drug used in the treatment of certain types of low-grade (slow-growing) lymphoma. This factsheet explains what it is, who can have it, how it is given, the benefits and possible side effects.

Cover image of 'Other targeted drugs for lymphoma'

Other targeted drugs for lymphoma (February 2020)

Lymphoma Action

This factsheet is about some of the other targeted drugs approved for people with lymphoma. It explains what types of targeted drugs are available: radioimmunotherapy; cell signal blockers; proteasome inhibitors; and immunomodulators.

Cover image of 'Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer. Information for the public'

Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer. Information for the public (January 2020)

National Institute for Health and Care Excellence (NICE)

Information about palbociclib (Ibrance), with fulvestrant, which is available through the Cancer Drugs Fund, and which may be used to treat hormone receptor-positive, HER2-negative, advanced breast cancer.

Cover image of 'Nivolumab (OPDIVO®)  [Polish]'

Nivolumab (OPDIVO®) [Polish] (January 2020)

Macmillan Cancer Support

Nivolumab (OPDIVO®) is a targeted therapy drug used to treat melanoma, non-small cell lung cancer or kidney (renal cell) cancer. 

Cover image of 'Ipilimumab [Polish]'

Ipilimumab [Polish] (January 2020)

Macmillan Cancer Support

Ipilimumab is a targeted therapy drug used to treat advanced melanoma. This describes how it works, how it is given, and some of the possible side-effects.

Cover image of 'Targeted therapies'

Targeted therapies (June 2019)

Ovacome

This factsheet has information about targeted therapies that can be used to treat ovarian cancer. It describes how they are used, their risks and benefits and how to access them. 

Cover image of 'Complementary therapies'

Complementary therapies (August 2019)

Ovacome

This briefing looks at the complementary therapies that are most commonly used by people with ovarian cancer, how they can help to manage treatment side effects and improve quality of life.

Cover image of 'Advanced prostate cancer'

Advanced prostate cancer (May 2019)

Prostate Cancer UK

Factsheet for men who have been diagnosed with advanced (metastatic) prostate cancer. It explains what advanced prostate cancer is, and describes how it is diagnosed, the grading and staging, and the treatment options (hormone therapy).

Sorry, no publications found.
Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm